CHRM4 and neoplasm: In summary, ADT‐induced CHRM4 overexpression and activation drives NEtD and immunosuppressive tumor environment through AKT/MYCN/IFNA17 axis, which confers targeting CHRM4 as a potential treatment for NEPC.